ProCan® de-risks, accelerates and decreases the cost of oncology clinical trials.
Joined September 2024
- Tweets7
- Following3
- Followers4
- Likes0
A reminder that this is your last chance to register for the ProCan® Technologies live webinar “Unlocking Proteomics for Smarter Antibody–Drug Conjugate (ADC) Development’’ being held on Thursday 26th June which features Prof Roger Reddel. Register here: events.teams.microsoft.com/e…
ALT A person operates scientific equipment in a laboratory. Overlaid text reads: "ProCan® TECHNOLOGIES – Unlocking Proteomics for Smarter ADC Development: From Target Discovery to Clinical Translation. Thu, 26 Jun, 4:00 PM – 5:15 PM AEST, Online event
13
🧪Speakers:
– Prof Roger Reddel (ProCan / @CMRI_AUS)
– Dr Jia (Jenny) Liu (St Vincent’s Hospital)
– Prof Paul Waring (@UniMelb / TissuPath)
– Moderator: Matthew Britland (MedWise Consulting)
📎 Register to attend (no cost):
events.teams.microsoft.com/e…
1
35
🧬Key Topics:
• Translational and clinical challenges in ADC development
• Gaps in current biomarker strategies and why proteomics matters
• How the ProCan ADC Panel is being applied across the development pipeline
• Perspectives from pathology, oncology, and industry experts
1
1
23
Whether you're working in translational science, medical affairs, biomarker discovery, oncology trials, or drug development—this live webinar is designed to inform and connect.
1
1
9
Thursday 26 June | 4–5:15 PM AEST
ProCan® Technologies is hosting a live, expert-led webinar exploring how mass spectrometry-based proteomics is being applied to improve Antibody–Drug Conjugate development—from target discovery to clinical evaluation and patient stratification.
ALT Four individuals, each in different professional settings: one in a suit and tie, one in a black blazer in a lab, one with white hair resting their chin on their hands, and one in a brown checkered blazer with a white shirt.
1
1
24
ProCan Technologies Limited has launched the new TargetQuant™ ADC Panel at @IAmBiotech #BIO2025 in Boston today - a multi-protein target screening panel designed to improve oncology research and clinical trial outcomes globally. Read more: cmrijeansforgenes.org.au/new… #ProCanTech
ALT Laboratory setting with multiple people in white lab coats working at various stations. They are using computers, handling samples, and operating scientific equipment.
A global collaboration with @InescID has led to #MOSA, a groundbreaking #AI method transforming #cancer research! MOSA fills gaps in multi-omic data, boosting datasets by 32.7% for 1,500+ cancer cell lines. Learn more: cmrijeansforgenes.org.au/new…
1
15